Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.53 |
| ▸ | LTA4H | P09960 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 3/20 | 0.50 |
| ▸ | DRD4 | P21917 | 3/20 | 0.50 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.50 |
| ▸ | SCN4A | P35499 | 2/20 | 0.49 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874431 | 0.88 | S1PR5 (0.48) | S1PR5DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL882579 | 0.88 | S1PR5 (0.48) | S1PR5DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL875284 | 0.88 | S1PR5 (0.48) | S1PR5DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL875727 | 0.88 | S1PR5 (0.48) | S1PR5DRD2DRD4DRD3SIGMAR1 | |
| SCHEMBL1708063 | 0.87 | L3MBTL1 (0.57) | S1PR5LTA4H | |
| SCHEMBL15566220 | 0.87 | SLC18A3 (0.52) | MCHR1DRD2DRD4ACHESCN4A | |
| SCHEMBL1282201 | 0.86 | LTA4H (0.65) | S1PR5LTA4HDRD2DRD4ACHE | |
| SCHEMBL22863935 | 0.86 | LTA4H (0.65) | S1PR5LTA4HDRD2DRD4ACHE | |
| SCHEMBL24027124 | 0.86 | MCHR1 (0.50) | MCHR1DRD2DRD4SCN4ASIGMAR1 | |
| SCHEMBL7818044 | 0.85 | SLC6A2 (0.56) | MCHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9181234-B2 | Antibacterial compounds | BIOTA EUROPE LTD. (GB) | 2015-11-10 | — | — | US | disclosed |
| EP-2625178-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | Biota Europe Ltd (GB) | 2013-08-14 | — | — | EP | disclosed |
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | BIOTA EUROPE LTD. (GB) | 2012-04-12 | — | — | US | disclosed |
| WO-2012045124-A1 | BACTERIA TOPOISOMERASE II INHIBITING 2-ETHYLCARBAMOYLAMINO-1, 3-BENZOTHIAZOL-5-YLS | BIOTA EUROPE LTD (GB) | 2012-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120088750-A1 | ANTIBACTERIAL COMPOUNDS | MRPL21, NISCH, LSS | S1PR5 4675/4885LTA4H 1358/4885MCHR1 4477/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.